Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$4.56 – $12.00
88% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.1K | $3.1K | $48.2K | $119.9K | $334.0K | $8.8K | $19.6K | $0 |
| Gross profit | −$1.1K | −$3.1K | −$48.2K | −$119.9K | −$334.0K | −$8.8K | −$19.6K | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $1.0M | $917.5K | $892.8K | $2.0M | $2.6M | $8.8K | $19.6K | $18.4M |
| Operating income | −$1.6M | −$2.2M | −$2.8M | −$6.6M | −$8.4M | −$15.5K | −$27.8K | −$26.5M |
| EBITDA | −$1.2M | −$2.2M | −$1.6M | −$4.6M | −$8.1M | −$15.5K | −$27.8K | −$26.5M |
| Net income | −$1.2M | −$1.9M | −$1.6M | −$15.5M | −$11.3M | −$15.9K | −$28.1K | −$24.9M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -0.30 | -0.33 | -0.58 | -7.68 | -3.84 | -0.00 | -0.00 | -20.40 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-0.15 | $-0.15–$-0.15 | 1 |
| 2027 | $0 | $-0.16 | $-0.16–$-0.16 | 1 |
| 2028 | $0 | $-0.14 | $-0.14–$-0.14 | 1 |
| 2029 | $14M | $-0.09 | $-0.09–$-0.09 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds MSCLF.
No tracked institution reports a position in MSCLF as of their last filing.
| Execution date | Ratio |
|---|---|
| 2026-01-30 | 1-for-12reverse |
No one on the platform has traded MSCLF yet.
| $160M |
| — |
| PBIGFParadigm Biopharmaceuticals Limited | $0.13 | -10.20% | $57M | — |
| POLBFPoolbeg Pharma PLC | $0.10 | +0.00% | $67M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.